Oxygen-Generating Nanoparticle
Solid Tumors (hypoxia sensitizer)
Pre-clinicalActive
Key Facts
About StimOxyGen
StimOxyGen is a private, pre-clinical stage biotech spin-out from Ulster University, founded in 2017 to commercialize over 15 years of academic research. The company's novel platform aims to overcome tumor hypoxia, a significant unmet clinical need that limits the success of many cancer treatments. Led by a team with strong scientific and entrepreneurial credentials, StimOxyGen is developing its lead nanoparticle program to sensitize resistant tumors to existing therapies, potentially improving outcomes for a broad range of solid tumors.
View full company profile